Musculoskeletal News and Research

RSS

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies, Inc. (a privately held development stage company) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold.

19 Dec 2014

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition.

17 Dec 2014

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program.

16 Dec 2014

Intronix Technologies, Western University collaborate to develop rehabilitation devices

Intronix Technologies will be collaborating with Western University's Department of Electrical and Computer Engineering to develop technology to be incorporated into rehabilitation devices.

16 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.

11 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.

8 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

CareCore, MedSolutions complete merger agreement

CareCore National, LLC and MedSolutions, Inc., two leading providers of Specialty Benefits Management (SBM) services to managed care organizations and risk-bearing provider organizations, today announced the completion of a merger that will help advance the companies' collective commitment to containing healthcare costs and achieving quality medical outcomes.

4 Dec 2014

Disease-associated malnutrition imposes economic burden on society

Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition. Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition and supported by Abbott.

4 Dec 2014

BME announces launch of Speed Arc Nitinol Fixation System

BioMedical Enterprises announced the launch of the Speed Arc Nitinol Fixation System, the world's first superelastic shape memory fixation device that conforms to the sloping surface of the metaphyseal anatomy. This addition to the current patented BME Speed Fixation System is available in three different sizes to ensure a proper fit in varying patient anatomies.

4 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Orthopedic surgeons recommend prompt medical attention for shoulder dislocations

Prompt and appropriate treatment of a dislocated shoulder--when the head of the upper arm bone (humerus) is completely knocked out of the shoulder socket (glenoid)--can minimize risk for future dislocations as well as the effects of related bone, muscle and nerve injuries, according to a literature review appearing in the December issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

2 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

Kessler Institute provides tips to help reduce risk of injury during winter months

Winter appears to have arrived early, bringing with it record snowfalls and cold temperatures across the country. It also brings an increased risk for injuries. Whether shoveling snow, dealing with icy roads, or simply trying to walk on wet, slippery pavement, caution is the key word.

29 Nov 2014

$A practical toolkit to implement coordinator-based fracture liaison services$

A practical toolkit to implement coordinator-based fracture liaison services

Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.

27 Nov 2014

Two medical research bodies announce new research centre to tackle musculoskeletal disorders

A major new research centre to tackle the impact of musculoskeletal disorders on people's ability to work has been announced by two leading medical research bodies.

24 Nov 2014

Musculoskeletal News and Research

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Intronix Technologies, Western University collaborate to develop rehabilitation devices

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

CareCore, MedSolutions complete merger agreement

Disease-associated malnutrition imposes economic burden on society

BME announces launch of Speed Arc Nitinol Fixation System

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Orthopedic surgeons recommend prompt medical attention for shoulder dislocations

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Kessler Institute provides tips to help reduce risk of injury during winter months

A practical toolkit to implement coordinator-based fracture liaison services

Two medical research bodies announce new research centre to tackle musculoskeletal disorders

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News